The Application of Radiolabeled Targeted Molecular Probes for the Diagnosis and Treatment of Prostate Cancer

Overview

Journal Korean J Radiol

Specialty Radiology

Date 2023 Jun 4

PMID 37271211

Authors

Luyi Cheng

Tianshuo Yang

Jun Zhang

Feng Gao

Lingyun Yang

Weijing Tao

Affiliations

Soon will be listed here.

Abstract

Radiopharmaceuticals targeting prostate-specific membrane antigens (PSMA) are essential for the diagnosis, evaluation, and treatment of prostate cancer (PCa), particularly metastatic castration-resistant PCa, for which conventional treatment is ineffective. These molecular probes include [Ga]PSMA, [F]PSMA, [AlF]PSMA, [Tc]PSMA, and [Zr]PSMA, which are widely used for diagnosis, and [Lu]PSMA and [Ac]PSMA, which are used for treatment. There are also new types of radiopharmaceuticals. Due to the differentiation and heterogeneity of tumor cells, a subtype of PCa with an extremely poor prognosis, referred to as neuroendocrine prostate cancer (NEPC), has emerged, and its diagnosis and treatment present great challenges. To improve the detection rate of NEPC and prolong patient survival, many researchers have investigated the use of relevant radiopharmaceuticals as targeted molecular probes for the detection and treatment of NEPC lesions, including DOTA-TOC and DOTA-TATE for somatostatin receptors, 4A06 for CUB domain-containing protein 1, and FDG. This review focused on the specific molecular targets and various radionuclides that have been developed for PCa in recent years, including those mentioned above and several others, and aimed to provide valuable up-to-date information and research ideas for future studies.

Citing Articles

Advancements in molecular imaging probes for precision diagnosis and treatment of prostate cancer.

Fang J, Alhaskawi A, Dong Y, Cheng C, Xu Z, Tian J J Zhejiang Univ Sci B. 2025; 26(2):124-144.

PMID: 40015933 PMC: 11867783. DOI: 10.1631/jzus.B2300614.

Future Prospect of Low-Molecular-Weight Prostate-Specific Membrane Antigen Radioisotopes Labeled as Theranostic Agents for Metastatic Castration-Resistant Prostate Cancer.

Ismuha R, Ritawidya R, Daruwati I, Muchtaridi M Molecules. 2025; 29(24.

PMID: 39770150 PMC: 11679579. DOI: 10.3390/molecules29246062.

Prostate-Specific Membrane Antigen-Positron Emission Tomography-Guided Radiomics and Machine Learning in Prostate Carcinoma.

Maes J, Gesquiere S, Maes A, Sathekge M, Van de Wiele C Cancers (Basel). 2024; 16(19).

PMID: 39409989 PMC: 11475246. DOI: 10.3390/cancers16193369.

Promising therapy for neuroendocrine prostate cancer: current status and future directions.

Fei X, Xue J, Wu J, Yang C, Wang K, Ma Q Ther Adv Med Oncol. 2024; 16:17588359241269676.

PMID: 39131727 PMC: 11311189. DOI: 10.1177/17588359241269676.

Carrier systems of radiopharmaceuticals and the application in cancer therapy.

Zhang T, Lei H, Chen X, Dou Z, Yu B, Su W Cell Death Discov. 2024; 10(1):16.

PMID: 38195680 PMC: 10776600. DOI: 10.1038/s41420-023-01778-3.

References

Sprute K, Kramer V, Koerber S, Meneses M, Fernandez R, Soza-Ried C . Diagnostic Accuracy of F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence. J Nucl Med. 2020; 62(2):208-213. PMC: 8679593. DOI: 10.2967/jnumed.120.246363. View

Piron S, Verhoeven J, De Coster E, Descamps B, Kersemans K, Pieters L . Impact of the molar activity and PSMA expression level on [F]AlF-PSMA-11 uptake in prostate cancer. Sci Rep. 2021; 11(1):22623. PMC: 8604919. DOI: 10.1038/s41598-021-02104-6. View

Banerjee S, Kumar V, Lisok A, Chen J, Minn I, Brummet M . Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy. Eur J Nucl Med Mol Imaging. 2019; 46(12):2545-2557. PMC: 8068522. DOI: 10.1007/s00259-019-04434-0. View

Bakht M, Derecichei I, Li Y, Ferraiuolo R, Dunning M, Oh S . Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocr Relat Cancer. 2018; 26(2):131-146. DOI: 10.1530/ERC-18-0226. View

Parsi M, Desai M, Desai D, Singhal S, Khandwala P, Potdar R . PSMA: a game changer in the diagnosis and treatment of advanced prostate cancer. Med Oncol. 2021; 38(8):89. DOI: 10.1007/s12032-021-01537-3. View

Kabunda J, Gabela L, Kalinda C, Aldous C, Pillay V, Nyakale N . Comparing 99mTc-PSMA to 99mTc-MDP in Prostate Cancer Staging of the Skeletal System. Clin Nucl Med. 2021; 46(7):562-568. PMC: 8174142. DOI: 10.1097/RLU.0000000000003702. View

Hennrich U, Eder M . [Lu]Lu-PSMA-617 (Pluvicto): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer. Pharmaceuticals (Basel). 2022; 15(10). PMC: 9608311. DOI: 10.3390/ph15101292. View

Hohberg M, Kobe C, Krapf P, Tager P, Hammes J, Dietlein F . Biodistribution and radiation dosimetry of [F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer. EJNMMI Res. 2019; 9(1):66. PMC: 6658635. DOI: 10.1186/s13550-019-0540-7. View

Dietlein F, Hohberg M, Kobe C, Zlatopolskiy B, Krapf P, Endepols H . An F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with F-JK-PSMA-7 During the First Year of Application. J Nucl Med. 2019; 61(2):202-209. DOI: 10.2967/jnumed.119.229542. View

10.

Dalm S, Bakker I, de Blois E, Doeswijk G, Konijnenberg M, Orlandi F . 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology. J Nucl Med. 2016; 58(2):293-299. DOI: 10.2967/jnumed.116.176636. View

11.

Okamoto I, Nokihara H, Nomura S, Niho S, Sugawara S, Horinouchi H . Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(5):e196828. PMC: 7068674. DOI: 10.1001/jamaoncol.2019.6828. View

12.

Wester H, Schottelius M . PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy. Semin Nucl Med. 2019; 49(4):302-312. DOI: 10.1053/j.semnuclmed.2019.02.008. View

13.

Cytawa W, Seitz A, Kircher S, Fukushima K, Tran-Gia J, Schirbel A . Ga-PSMA I&T PET/CT for primary staging of prostate cancer. Eur J Nucl Med Mol Imaging. 2019; 47(1):168-177. DOI: 10.1007/s00259-019-04524-z. View

14.

Rahbar K, Afshar-Oromieh A, Jadvar H, Ahmadzadehfar H . PSMA Theranostics: Current Status and Future Directions. Mol Imaging. 2018; 17:1536012118776068. PMC: 5992796. DOI: 10.1177/1536012118776068. View

15.

Barbato F, Fendler W, Rauscher I, Herrmann K, Wetter A, Ferdinandus J . PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease. J Nucl Med. 2021; . PMC: 8612183. DOI: 10.2967/jnumed.121.262120. View

16.

Park S, Na S, Kumar M, Mosci C, Wardak M, Koglin N . Clinical Evaluation of (4S)-4-(3-[F]Fluoropropyl)-L-glutamate (F-FSPG) for PET/CT Imaging in Patients with Newly Diagnosed and Recurrent Prostate Cancer. Clin Cancer Res. 2020; 26(20):5380-5387. DOI: 10.1158/1078-0432.CCR-20-0644. View

17.

Siow A, Kowalczyk R, Brimble M, Harris P . Evolution of Peptide-Based Prostate-Specific Membrane Antigen (PSMA) Inhibitors: An Approach to Novel Prostate Cancer Therapeutics. Curr Med Chem. 2020; 28(19):3713-3752. DOI: 10.2174/0929867327666201006153847. View

18.

Cheng S, Lang L, Wang Z, Jacobson O, Yung B, Zhu G . Positron Emission Tomography Imaging of Prostate Cancer with Ga-68-Labeled Gastrin-Releasing Peptide Receptor Agonist BBN and Antagonist RM26. Bioconjug Chem. 2017; 29(2):410-419. PMC: 5824342. DOI: 10.1021/acs.bioconjchem.7b00726. View

19.

Murthy V, Sonni I, Jariwala N, Juarez R, Reiter R, Raman S . The Role of PSMA PET/CT and PET/MRI in the Initial Staging of Prostate Cancer. Eur Urol Focus. 2021; 7(2):258-266. DOI: 10.1016/j.euf.2021.01.016. View

20.

Dreyfuss A, Ahn G, Barsky A, Gillman J, Vapiwala N, Pantel A . 18F-Fluciclovine PET/CT in Therapeutic Decision Making for Prostate Cancer: A Large Single-Center Practice-Based Analysis. Clin Nucl Med. 2020; 46(3):187-194. DOI: 10.1097/RLU.0000000000003444. View